natgillin/translations-raw huggingface dataset:
An anti-STAT3 single domain antibody (sdAb) comprising an amino acid sequence as set forth in SEQ ID NO:3 or SEQ ID NO:4. 
Izolirani polipeptid, naznačen time što izolirani polipeptid sadrži anti-STAT3 antitijelo s jednom domenom (sdAb) koje sadrži aminokiselinsku sekvencu kao što je navedena u SEQ ID NO:3.
The pharmaceutical composition according to any one of claims 1 to 12, wherein the composition provides, in healthy humans, a mean plasma concentration value not exceeding 3.5µg Imatinib/mL, when dosed 2 hours after a light breakfast. 
Farmaceutski sastav prema bilo kojem od Zahtjeva 1 do 12, naznačen time, da sastav opskrbljava, kod zdravih ljudi, prosječnu vrijednost koncentracije u plazmi koja ne prelazi 3,5ug Imatinib/mL, kada se dozira 2 sata nakon laganog doručka.
cultivating a cell, comprising a nucleic acid encoding the immunoglobulin 
kultiviranje stanice koja sadrži nukleinsku kiselinu koja kodira anti-HER2 protutijelo,
Here, the BOM-acid, Formula 36, (3.8 g, ˜1.0 mmol) was dissolved in DCM (30 mL), stirred and cooled in an ice-water bath at 0° C. under N2. 
Ovdje je BOM-kiselina, formula 36 (3.8 g, -10.0 mmol) bila otopljena u DCM (30 mL), izmiješana i ohlađena u kupelji led-voda kod 0*C pod N».
and tautomers, stereoisomers, pharmaceutically acceptable salts, or hydrates thereof. 
i njihovi tautomeri, stereoizomeri, njihove farmaceutski prihvatljive soli, ili njihovi hidrati.
Crystalline monohydrate of the compound of formula (IV) 
Kristalni monohidrat, naznačen time, što je spoj formule (IV) [image]
-(X)- is a bond, and is selected from -CH3; 
je –(X)-R4, gdje (X)- je veza, i je odabran od sljedećih:
The compound for use according to claim 6, wherein the transplantation rejection disease is graft versus host disease. 
Sol spoja za uporabu prema patentnom zahtjevu 5, pri čemu je bolest odbacivanja transplantata bolest presatka protiv domaćina.
The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, wherein R2 is a phenyl group, a pyridyl group, a pyridazinyl group or a pyrimidyl group (said phenyl group, pyridyl group or pyrimidyl group may be substituted by 1-3 halogen atoms or methoxy groups), a pyridonyl group, or a pyrimidinonyl group. 
Spoj ili njegova farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 4, naznačen time da R2 je fenil skupina, piridil skupina, piridazinil skupina ili pirimidil skupina (navedena fenil skupina, piridil skupina ili pirimidil skupina mogu biti supstituirane s 1-3 atoma halogena ili metoksi skupinama), piridonil skupina, ili pirimidinonil skupina.
said second thermoplastic polymer material and said fourth polymer material have a Shore A hardness of 70 to 60; 
što drugi termoplastični polimerni materijal 1 četvrti polimerni materijal imaju Shore A tvrdoću od 70 do 60;
In one embodiment of the invention there is provided a process in which the poultry litter is combusted at a temperature of the order of 850° C. for at least two seconds. 
Postupak prema zahtjevu 1 gdje se otpad od peradi termički obrađuje na temperaturi u vrijednosti od 850%C najmanje dvije sekunde.
Compositions for inhalation may comprise aerosol or other atomizable formulations or dry powder formulations. 
Sastavi za inhalaciju mogu sadržavati aerosol ili druge formulacije koje se mogu atomizirati ili formulacije suhog praha.
measuring a size of the DNA molecule; 
mjerenja veličine molekule DNK;
A compound of the formula (I), wherein 
(i) atom halogena, i
After filtration the solvent is removed in vacuo to give the titled product which is used crude in the next step. 
Nakon filtracije otapalo se odstrani u vakuumu, čime se dobije naslovni proizvod koji se upotrebljava sirov u slijedećem stupnju.
∘ cyano-; • R11 is chosen from the following list L3: 
R11 je odabran sa popisa L3 koji sadrži: o halogen-; o
the term R3 designate a radical selected from the group consisting of H, halogen, C1. 6-alkyl, C4-6-cycloalkyl, C2-6-alkenyl and C2-6-alkynyl; 
oznaka R3 označava radikal odabran iz skupine koja se sastoji od H, halogena, C1-6-alkila, C4-6-cikloalkila, C2-6-alkenila i C2-6-alkinila;
A therapeutic formulation, consisting of: sulpiride (1); 
Terapijska formulacija, koji se sastoji od, (1) sulpirida (1);
A track arrangement with an angled guide plate according to claim 1 . 
Sklop kolosijeka naznačen time da ima kutne ploče vodilice prema jednom od prethodnih zahtjeva.
The core for rolls of sheet material according to the invention comprises a corrugated side wall. 
Sukladno izumu, jezgra za svitke laminata sastoji se od valovite bočne stijenke.
More particularly, the invention relates to a pharmaceutical composition comprising 0.01 mg to 0.9 mg of aleglitazar or a salt thereof obtainable by 
Farmaceutski sastav, naznačen time, da sadrži 0,01 mg do 0,9 mg aleglitazara ili njegove soli, koji se dobiva pomoću:
In another aspect of the invention, there is provided 3, 1 1b- cis -dihydrotetrabenazine for use in the prophylactic treatment of a patient identified as carrying the mutant gene responsible for Huntington's disease, wherein the prophylactic treatment is for preventing or slowing down sub-clinical progression of the disease in a patient. 
U skladu s tim, u slijedećem aspektu izuma, osiguran je spoj za uporabu u profilaktičnom liječenju Huntington-ove bolesti kod pacijenta kod kojeg je ustanovljeno da nosi mutantni gen odgovoran za Huntington-ovu bolest, pri čemu je spoj (+) izomer 3,11b-cis-dihidrotetrabenazina ili njegova farmaceutski prihvatljiva sol.
The method of claim 11 wherein step (b) heats the mixture of step (a) to approximately 110-120° C. 
Postupak prema patentnom zahtjevu 41, naznačen time što se smjesa zagrijava do približno 110-120%*C.
A method according to claim 8, wherein the cell is a fungal cell of a genus selected from the group consisting of Saccharomyces, Candida, Kluyveromyces, Hansenula, Schizosaccaromyces, Yarrowia, Pichia and Aspergillus. 
Metoda u skladu s patentnim zahtjevom 9, pri čemu je stanica stanica gljivice, poželjno odabrana iz grupe koja se sastoji od Saccharomyces, Candida, Kluyveromyces, Hansenula, Szhizosaccharomyces, YWarrowia, Pichia 1 Aspergillus.
perform intra prediction on the current block using the number of neighboring pixels and the location of the one or more neighboring pixels; obtain a residual using an intra predicted value of the current block and a pixel value of the current block; and 
Postupak za kodiranje slike, te postupak sadrži: provođenje intra predviđanja na trenutnom bloku u skladu s načinom intra predviđanja; dobivanje rezidualnih podataka koji pokazuju razliku između vrijednosti intra predviđanja i vrijednosti piksela trenutnog bloka;
or a pharmaceutically acceptable salt, tautomer, solvate or polymorph thereof, wherein 
Spoj s formulom (I) [image] ili njegova farmaceutski prihvatljiva sol, tautomer(i), solvat ili polimorf, naznačen time što
The method of claim 34, wherein the binding agent is present in an amount ranging from 0.01 wt% to 50 wt% of the second formulation, preferably from 0.01 wt% to 10 wt% of the second formulation. 
Postupak prema zahtjevu 34, naznačen time da je sredstvo za vezanje prisutno u količini koja je u opsegu od 0,01 mas.% do 50 mas.% druge formulacije, poželjno od 0,01 mas.% do 10 mas.% druge formulacije.
The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, wherein R1 is C6-10 aryl optionally substituted with 1 to 5 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 alkoxy, cyano, halo, hydroxy, amino, trifluoromethyl, and trifluoromethoxy. 
Spoj ili njegova farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 4, naznačen time što R1 je C6-10 aril po izboru supstituiran s 1 do 5 supstituenata koji su neovisno odabrani iz skupine koju čine C1-4 alkil, C1-4 alkoksi, cijano, halo, hidroksi, amino, trifluorometil, i trifluorometoksi.
Pharmaceutical composition according to claim 1, for the treatment of pathologies of the colon. 
Farmaceutski pripravci prema prethodnim patentnim zahtjevima namijenjeni liječenju patoloških stanja debelog crijeva
under suitable conditions to form an amide bond. The process of claim 1, further comprising a step of preparing the compound of formula 11: 
[image] pod uvjetima pogodnim za formiranje amidne veze; po želji nadalje obuhvaćajući korak pripreme spoja formule 11:
The antibody of any one of claims 1 to 4 or 9 for use in the prophylaxis or treatment of inflammatory and thrombotic disorders according to claim 13, wherein said disorder is peripheral arterial occlusive disease (PAOD) or critical limb ischemia (CLI). 
Protutijelo prema bilo kojem zahtjevu od 1 do 4 ili 9, naznačeno time, da se upotrebljava za profilaksu ili liječenje upalnih 1 trombotičkih poremećaja prema zahtjevu 13, pri čemu je spomenuti poremećaj okluzivna bolest perifernih arterija (PAOD) ili opasna ishemija ekstremiteta (CLI).
To a suspension of 2-ethoxy-4-nitro-benzonitrile (0.49 g, 2.54 mmol) in ethanol (50 ml) is added tin (II) chloride dihydrate (2.87 g, 12.7 mmol) and the suspension is stirred at 70 °C for 2 hours and at room temperature overnight. 
U suspenziju 2-etoksi-4-nitro-benzonitrila (0,49 g, 2,54 mmola) u etanolu (50 ml) doda se kositreni (II) klorid dihidrat (2,87 g, 12,7 mmola) i suspenziju se miješa 2 sata pri 70*C i pri sobnoj temperature preko noći.
The transdermal formulation according to any one of claims 1 to 4 for use in the treatment of a disease or disorder associated with reduced endogenous testosterone production in a male subject by transdermal administration. 
Formulacija za tretman bolesti ili poremećaja prema zahtjevu 15 ili 16, naznačena time, da navedena bolest ili poremećaj povezan sa smanjenom endogenom proizvodnjom testosterona je hipogonadizam.
A compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt, enantiomer, racemate, diastereomer, or mixture of diastereomers thereof, for use in treating pathological sequelae due to low levels of plasma HDL-cholesterol in a mammal. 
Spoj u skladu s bilo kojim od patentni zahtjeva 1 do 7 ili njegova farmaceutski prihvatljiva sol, enantiomer, racemat, dijastereomer ili smjesa dijastereomera, naznačen time što je namijenjen upotrebi u liječenju patoloških posljedica niskih razina HDL-kolesterola u plazmi kod sisavca.
detecting whether the target is recognised by a cognate binder. A method according to claim 31, wherein the binders are antibody molecules and the target is an antigen, or wherein the binders are TCRs and the target is an MHC:peptide complex. 
Postupak sukladno patentnom zahtjevu 31, naznačen time, da su vezujuća sredstva molekule protutijela i ciljno sredstvo je antigen, ili time, da su vezujuća sredstva TCR-ovi 1 ciljna struktura je MHC:peptidni kompleks.
The compound of claim 6, wherein X41 is NR42, and R42 is selected from the group consisting of —H, a lower alkyl, a lower cycloalkyl, —C(O)N(R27)2, and —C(O)OH, wherein each R27 is independently —H or a lower alkyl. 
Spoj prema zahtjevu 19, pri čemu Xu, je NR, 1 R4, je izabran iz skupine koju čine -H, niži alkil, niži cikloalkil, - C(O)N(R27)2, 1 -C(O)OH, pri čemu svaki R2; je nezavisno -H ili niži alkil.
Suitable chlorooxime formation conditions comprise adding HCl in dioxame to a solution of the oxime in the presence of NCS in a suitable solvent selected from a nonprotic solvents (DCM, DCE, THF, and dioxane), aromatic hydrocarbons (e.g. toluene, xylenes), and alkyl acetates (e.g., isopropyl acetate, ethyl acetate). 
ši reakcijom spoja formule 4-i: pod pogodnim uvjetima stvaranja klorooksima. 15 5. > Postupak u skladu s patentnim zahtjevom 4, naznačen time, da pogodni uvjeti stvaranja klorooksima obuhvaćaju dodavanje HCI u dioksanu otopini spoja formule 4-i u prisutnosti NCS-a u pogodnom otapalu odabranom od neprotonskih otapala, aromatskih ugljikovodika i alkil acetata.
Therefore, in a preferred embodiment the pharmaceutical composition according to the present invention additionally contains at least one antigen presenting cell. 
Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 6, koji dodatno sadrži najmanje jednu stanicu koja predstavlja antigen.
Fig. 24 shows a prior art packaging. The packaging is an example of the known packages, which cannot be bent more than approximately 190° (a) and not up to 240°, and thus, it cannot be packed in an usual automated packing machine, as the packaging according to the invention. 
Slika 24 prikazuje pakiranje iz stanja tehnike. Ovo pakiranje je jedan primjer od poznatih pakiranja, koja se ne mogu savijati za više od približno 190" (a) niti sve do 240", i stoga ne može biti pakirano u uobičajenim automatiziranim strojevima za pakiranje, kao što to može biti pakiranje koje je u skladu ovim izumom.
The rim block cage according to one of the preceding claims, characterized in that the containers (3a, 3b, 3c, 3d) are integrally interconnected. 
WC košarica prema jednom od prethodnih zahtjeva, naznačena time da su spremnici (3a, 3b, 3c, 3d) oblikovani međusobno cjelovito.
The results obtained are presented in the following graphs. 
Dobiveni rezultati su predstavljeni u sljedećim grafikonima.
The floating lake system of claim 4, wherein the plurality of layers can be of the same or different materials and have different permeability. 
Sustav plutajućeg jezera prema zahtjevu 17, naznačen time što mnoštvo slojeva može biti od istog ili različitih materijala i koji mogu imati različite propusnosti.
X− is a physiologically acceptable anion, such as chloride, bromide, iodide, hydroxide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate and p-toluenesulfonate. 
X- je fiziološki prihvatljiv anion kojeg se bira iz skupine koju čme klorid, bromid, jodid, hidroksid, sulfat, nitrat, fosfat, acetat, trifluoracetat, fumarat, citrat, tartarat, oksalat, sukcinat, mandelat, metansulfonat i p-toluensulfonat.
The mouse of claim 1 or 2, wherein the humanized immunoglobulin heavy chain variable region locus comprises an insertion of one or more human VH gene segments, one or more human DH gene segments, and one or more human JH gene segments. 
Miš u skladu s patentnim zahtjevom 1, naznačen time, da miš ima genom koji sadržava brisanje jednog ili više segmenata varijabilnog područja imunoglobulina miša i umetanje segmenata varijabilnog humanog područja i pri čemu mišu nedostaje funkcionalni endogeni mišji lokus ADAM6.
A pharmaceutical combination that comprises a pharmaceutical formulation according to claim 1 and an anti-diabetic, wherein the anti-diabetic is a sulfonylurea, thiazolidinedione, alpha glucosidase inhibitor, meglitinide, glucagon-like peptide (GLP) agonist, insulin, amylin agonist, fructose 1,6-bis phosphatase inhibitor, insulin secretagogue, insulin sensitizer, glucokinase activator, glucocorticoid antagonist, AMP kinase activator, modulators of the incretin pathway such as incretin secretagogue, incretin mimic, incretin potentiator, bile acid sequestrant or bile acid receptor agonist such as TGR5 agonist, dopamine receptor agonist, aldose reductase inhibitor, PPARY agonist, PPARa agonist, PPARδ antagonist or agonist, PPARa/Y dual agonist, 11-B-HSD-1 inhibitor, dipeptidyl peptidase IV (DPP4) inhibitor other than saxagliptin, SGLT2 inhibitor other than dapagliflozin, glucagon-like peptide-1 (GLP-1), GLP-1 agonist, or PTP-1B inhibitor. 
Farmaceutska kombinacija naznačena time da sadrži farmaceutsku formulaciju prema zahtjevu 1 i anti-dijabetičko sredstvo, pri čemu anti-dijabetičko sredstvo je sulfonilurea, tiazolidindion, inhibitor alfa glukozidaze, meglitinid, agonist glukagonu sličnog peptida (GLP), inzulin, agonist amilina, inhibitor fruktoza 1,6-bis fosfataze, sekretagog inzulina, senzitizator inzulina, aktivator glukokinaze, glukokortikoidni antagonist, aktivator AMP kinaze, modulatori inkretinskog puta kao što je sekretagog inkretina, mimetik inkretina, potencijator inkretina, sekvestrant žučne kiseline ili agonist receptora žučne kiseline kao što je agonist TGRS, agonist receptora dopamina, inhibitor aldoza reduktaze, PPARy agonist, PPARa agonist, PPARÅ antagonist ili agonist, PPARo/y dual agonist, 11-f- HSD-1 inhibitor, inhibitor dipeptidil peptidaze IV (DPP4) različit od saksagliptina, inhibitor SGLT2 različit od dapagliflozina, glukagonu sličan peptid-1 (GLP-1), agonist GLP-I, ili inhibitor PTP-1B.
wherein a scan pattern for scanning flags indicating non-zero coefficients of each subset is same with the scan pattern for scanning non-zero coefficients of each subset. The method of claim 1, wherein, when the intra prediction mode is a vertical mode, the scan pattern for scanning the plurality of subsets is a horizontal scan. 
Uređaj prema zahtjevu 1, naznačen time da entropijski koder (130) kodira položaje ne-nultih koeficijenata i informacije za identifikaciju ne-nultih koeficijenata svakog pod-bloka. . Uređaj prema zahtjevu 1, naznačen time da je unutarokovirni način predviđanja horizontalni način, a obrazac skeniranja je vertikalni način skeniranja.
The compound according to any one of claims 26 to 29, or the pharmaceutically acceptable salt thereof or the solvate thereof, wherein substituent group D is carbocyclic group optionally substituted by substituent group C, heterocyclic group optionally substituted by substituent group C, carbocycle lower alkyl optionally substituted by substituent group C, or heterocycle lower alkyl optionally substituted by substituent group C (wherein substituent group C is same as that of claim 13). 
(pri čemu Supstituentska skupina C ima isto značenje kao što je navedeno u zahtjevu 13). Spoj prema bilo kojem od zahtjeva 26 do 29, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat, naznačen time, da Supstituentska skupina D je karbociklička skupina prema potrebi supstituirana sa supstituentskom skupinom C, heterociklička skupina prema potrebi supstituirana sa supstituentskom skupinom C, karbociklički niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, ili heterociklički niži alkil prema potrebi supstituiran sa supstituentskom skupinom C,
The method of any one of claims 1-4, wherein the weighting factor a is about 0.33. 
Metoda zahtjeva 1 do 7, pri čemu je gdje je a težinski faktor oko 0.33.
In clinical phase I studies of ET-743, promising responses were observed in patients with sarcoma and breast and ovarian carcinoma. 
U kliničkoj fazi I ispitivanja ET-743, zabilježeni su obećavajući odgovori kod pacijenata sa sarkomom i karcinomom dojke i jajnika.
A device as claimed in any one of the claims 11-12, wherein the heating zone is a heat exchanger comprising at least one pipe or tube surrounded by a heat transfer medium not being in direct contact with the slurry of expandable microspheres. 
Uređaj u skladu s bilo kojim od patentnih zahtjeva 11-12, naznačen time što je zona grijanja izmjenjivač topline koji sadrži najmanje jednu cijev ili crijevo okruženo medijem za prijenos topline koji nije u izravnom kontaktu s muljem od rastezljivih mikrosfera.
The pharmaceutical composition of claim 12, which further comprises a second active ingredient. 
Farmaceutska smjesa iz zahtjeva 4, naznačena time, što dalje sadrži drugi aktivni sastojak.
wherein said nucleic acid encodes a polypeptide, preferably an antibody, having the ability of binding to CLD18A2 but not to CLD18A1 and upon binding to CLD18A2 mediating killing of cells expressing CLD18A2 by T cells. 
Protutijelo iz patentnog zahtjeva 1 koje se veže za CLD18A1 i CLD18A2 ili se veže za CLD18A2 ali ne i za CLD18A1. Protutijelo iz patentnog zahtjeva 2 pri čemu CLD18A2 ima slijed aminokiselina prema SEQ ID NO: 2.
reacting the compound of the Formula IX with a compound of the Formula II: 
(1) reakcije spoja sa formulom IX sa spojem sa formulom II: o
The method of claim 10, wherein the cap includes a vent effective to disperse the fragrance. The method of claim 10, further comprising attaching the cap to the first end of the base with a locking mechanism, wherein the locking mechanism includes protrusions from the first end of the base and the cap is effective to snap onto the protrusions so that the cap is secured to the base. 
Postupak prema zahtjevu 4, naznačen time, da on dodatno obuhvaća priključivanje kapice (116) na drugi kraj baze s mehanizmom za zaključavanje, pri čemu mehanizam za zaključavanje obuhvaća izbočine iz drugog kraja baze, a kapica je djelotvorno uređena da škljocajem zahvati izbočine, kako bi se kapica (116) učvrstila za bazu (134).
The composition of any of claims 1 to 3, wherein the polyolefin is a polypropylene grafted with acrylic acid (PP-g-AA). 
Pripravak u skladu s patentnim zahtjevom 6 ili 7, naznačen time što je poliolefin polipropilen s nakalemljenom akrilnom kiselinom (PP-g-AA).
The method of claim 8, wherein the coins or coin blanks comprise a material selected from the group consisting of stainless steel, bronze, steel, copper, titanium, and brass, and the electroplated metal layer is selected from the group consisting of nickel, copper, and brass. 
Metalna podloga u skladu s patentnim zahtjevom 9, naznačena time što se metalnu podlogu bira iz skupine koju čine bakar, mjed, bronca, niskougljični čelik, nehrđajući čelik, te titanij.
A pharmaceutical composition which comprises as an active ingredient, an antibody or an antigen-binding fragment thereof according to any one of claims 1 to 12, a chimeric molecule according to claim 13, a chimeric antigen receptor according to claim 14, a cell according to claim 17 or a polynucleotide according to claim 15 or 16. 
Farmaceutski spoj koji sadrži kao aktivni sastojak, antitijelo ili njegov antigen-vezujući fragment u skladu s bilo kojim od patentnih zahtjeva 1 do 12, himernu molekulu u skladu s patentnim zahtjevom 13, himerni receptor antigena u skladu s patentnim zahtjevom 14, stanicu u skladu s patentnim zahtjevom 17 ili polinukleotid u skladu s patentnim zahtjevom 15 ili 16.
The antibody of claim 1, wherein the VL CDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO:1; the VL CDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO:2; the VL CDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO:3; the VH CDR1 comprises or consists of the amino acid sequence set forth in SEQ ID NO:4; the VH CDR2 comprises or consists of the amino acid sequence set forth in SEQ ID NO:5; and the VH CDR3 comprises or consists of the amino acid sequence set forth in SEQ ID NO:6. 
Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što VL CDR1 sadrži ili ga čini aminokiselinski slijed iznijet u SEQ ID NO:1; VL CDR2 sadrži ili ga čini aminokiselinski slijed iznijet u SEQ ID NO:2; VL CDR3 sadrži ili ga čini aminokiselinski slijed iznijet u SEQ ID NO:3; VH CDR1 sadrži ili ga čini aminokiselinski slijed iznijet u SEQ ID NO:4; VH CDR2 sadrži ili ga čini aminokiselinski slijed iznijet u SEQ ID NO:5; i VH CDR3 sadrži ili ga čini aminokiselinski slijed iznijet u SEQ ID NO:6.
The immunoconjugate according to any one of claims 19 to 20, wherein said cytotoxic agent is linked to said antibody with a cleavable linker, such as N -succinimydyl 4-(2-pyridyldithio)-pentanoate (SSP), maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB) or AV-1 K-lock valine-citrulline. 
Imunokonjugat prema bilo kojem od patentnih zahtjeva 19 do 20, naznačen time, da je navedeno citotoksično sredstvo povezano sa spomenutim protutijelom putem povezivača koji se može cijepati, kao što je N-sukcinimidil-4-(2-piridilditio)-pentanoat (SSP), maleimidokaproil-valin-citrulin-p-aminobenziloksikarbonil (mc-vc-PAB) ili AV-1-K-lock-valin-citrulin.
Another aspect of the present disclosure is a compound of the present invention for use in the treatment or prevention of a central nervous system disorder, inflammation, pain, or neovascularization. 
Spoj prema zahtjevu 1 ili 2 za upotrebu u liječenju ili prevenciji poremećaja središnjeg živčanog sustava, upale, boli ili neovaskularizacije.
a diluent or filler comprising a combination of microcrystalline cellulose and lactose; 
(b) otapalo ili sredstvo za punjenje koje sadrži kombinaciju mikrokristala celuloze i laktoze;